CellAct Pharma (Germany)

Recent papers from CellAct Pharma (Germany)

1. Inner ear distribution of the small, lipophilic pyridoindole AC102 after intratympanic drug deliveryJournal of Drug Delivery Science and Technology · 2026
2. Application of novel enzyme preparations for biogas production in practiceEnvironmental Technology · 2025
3. Assessment of Safety, Tolerability, Pharmacokinetics, and Volume-Dependent Conductive Hearing Loss in Healthy Volunteers: First-in-Human, Open-Label, Placebo-Controlled Study of a Single Intratympanic Injection of AC102Otology & Neurotology · 2025
4. A preoperative dose of the pyridoindole AC102 improves the recovery of residual hearing in a gerbil animal model of cochlear implantationCell Death and Disease · 2024
5. A single dose of AC102 restores hearing in a guinea pig model of noise-induced hearing loss to almost prenoise levelsProceedings of the National Academy of Sciences · 2024
6. A novel pyridoindole improves the recovery of residual hearing following cochlear implantation after a single preoperative application2024
7. Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II StudyCancers · 2020
8. A review of systemic therapy in biliary tract carcinomaJournal of Gastrointestinal Oncology · 2020
9. Prognostic Impact of Carboxylesterase 2 in CholangiocarcinomaScientific Reports · 2019
10. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiolBritish Journal of Clinical Pharmacology · 2015
11. Adiponectin is a negative regulator of antigen‐activated T cellsEuropean Journal of Immunology · 2011
12. HLA-DR Alpha 2 Mediates Negative Signalling via Binding to Tirc7 Leading to Anti-Inflammatory and Apoptotic Effects in Lymphocytes In Vitro and In VivoPLoS ONE · 2008